Boditech Med and SphingoTec Launch Kidney Function Diagnostic Assay

Boditech Med and SphingoTec have announced the release of the AFIAS sphingotest® penKid® assay. This diagnostic tool assesses kidney function in critically ill patients by measuring Proenkephalin A 119-159 (penKid). It is designed for enhanced clinical decision-making in acute care.

The assay is marked under the In Vitro Diagnostic Regulation and provides quantitative measurements crucial for diagnosing acute kidney injury, especially in cases involving sepsis. This product launch results from a licensing and market development agreement aimed at global commercialization.

Executives from both companies highlight the partnership's role in innovation and access to advanced diagnostics, with the assay positioned to improve patient care worldwide.